# 由 Gavi 領導的一項全球衛生新倡議，旨在加速開發針對 Bundibugyo 病株伊波拉病毒的試驗準備疫苗。

*biotech · news · 2026-06-09 · standardmedia.co.ke*

## Key points

- Gavi 與 CEPI 正合作在數月內加速開發 Bundibugyo 伊波拉疫苗。
- 此倡議不同於以往僅在疫情爆發後才開始疫苗研發的常規做法。
- Bundibugyo 伊波拉病株因市場需求不確定而缺乏疫苗投資。
- 該策略旨在解決針對罕見但致命病原體準備不足的市場失靈問題。

A new global health initiative led by Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) is aiming to fast-track the development of a trial-ready vaccine for the Bundibugyo strain of Ebola virus within months, marking a major shift away from the traditional approach of waiting for outbreaks before starting vaccine development. Gavi said the strategy is designed to close a long-standing gap in global epidemic preparedness, where rare and unpredictable pathogens receive limited commercial investment due to uncertain market returns. According to Gavi, this lack of demand certainty has historically slowed or discouraged manufacturers from investing in vaccines for less common Ebola strains such as Bundibugyo.

[Read the full story on standardmedia.co.ke](https://www.standardmedia.co.ke/health/health-science/article/2001549947/race-against-ebola-gavi-cepi-launch-fast-track-vaccine-plan-for-bundibugyo-strain)

---

Canonical: https://newsio.io/zh-TW/n/c1bfa924-55dd-48ca-8314-661a879cb32e/gavi-bundibugyo-gavi
Summarized by Newsio from standardmedia.co.ke. https://newsio.io/how-it-works